Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Deals Commercial Medical Device

Pacts In Medtech: November/December 2016

  • Analysis

Executive Summary

Derived from Strategic Transactions, Informa’s premium source for tracking life-sciences deals, this new bimonthly Pacts In Medtech column pulls up notable technology alliances, R&D partnerships and commercial collaborations. This month we highlight deals announced in November and December 2016.

You may also be interested in...



Deals In Depth: December 2022

The year's biggest M&A deal, along with billion dollar alliances marked out December's dealmaking credentials.

Deals In Depth: November 2022

Five $1bn+ alliances were penned in November. Topping the list was a potential $4.5bn deal between Arcturus Therapeutics and CSL Seqirus.

Deals In Depth: October 2022

Two $1bn+ alliances were penned in October. Financing reached $7.7bn in biopharma, $636m in device, and $140m in diagnostics.

Table

View full table

Topics

Related Companies

Tags:
Deals Commercial Medical Device
Latest Headlines

MDR Amendment Proposal Likely To Be Adopted In Two Weeks’ Time

EU Borderline Product Court Ruling Puts Tricky “Negative Burden Of Proof” On Manufacturers

Philips Healthcare Doubles Down On Creating An Agile Future

CDRH 2022: Shuren Says COVID-19 Left Agency ‘Battle-Scarred’ But Also Wiser

See All
UsernamePublicRestriction

Register

MT104274

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By